IBN heads into its July 17 earnings release with an unusual split: short interest building steadily, yet options traders leaning more bullish than they have in weeks.
The most striking setup is in the lending market — and it points firmly away from bear conviction. Borrow availability is extremely loose at roughly 2,165%, meaning more than 21 shares remain available in the lending pool for every one already borrowed. That reading has actually tightened from above 6,000% in early June, reflecting the uptick in short positioning, but it remains well above any level associated with squeeze pressure. Cost to borrow is low at 0.43%, down 14% on the week. The shorts piling in are not paying a premium for the privilege. Meanwhile, the ORTEX short score is a modest 32 — firmly in the lower third of its historical range — signalling that the overall short-side setup is far from extreme.
Options positioning tells the opposite story from the shorts. The put/call ratio has moved below its 20-day average, running at 0.53 against a mean of 0.60, placing it about one standard deviation on the bullish side. That is a notable shift: the PCR spent most of late June above 0.66, suggesting defensive positioning was dominant heading into Q2 earnings season. Traders have unwound that caution over the past week. The stock itself is up 5% over the past month to $29.26, but gave back 2.7% across the prior week before a 0.9% bounce on Monday — a pattern consistent with profit-taking ahead of the event rather than directional conviction either way.
The bull case heading into the print has clear support from recent fundamentals. A recent ORTEX note flagged Q1 net profit up 28% year-over-year to ₹7,368 crore, with net interest margin expansion and robust loan growth across both retail and corporate books. The EPS surprise factor score ranks in the 83rd percentile, reflecting a consistent track record of beating estimates. The analyst recommendation differential factor scores in the 91st percentile — suggesting the consensus has been upgrading faster than peers. The analyst data in the system is too stale to be actionable (last price target on record is from 2023), but the factor-score signal captures the directional drift of more recent coverage. Bears can point to a valuation re-rating: the price-to-book multiple has expanded roughly 0.14x over the past 30 days to 2.3x, compressing the margin of safety that made the stock attractive earlier in the year. Insider activity adds a mild cautionary note — CEO Sandeep Bakhshi and Executive Director Rakesh Jha both sold shares in late April, though the trade-significance scores were low and the transactions appear routine rather than alarming.
Institutional ownership provides a more supportive backdrop. GQG Partners added over 7 million shares in the most recent reported period, and BlackRock added nearly 2.8 million. SBI Funds Management added 27 million shares — the largest single move in the holder table. Against that flow, recent insider selling looks modest. The earnings report will test whether the 28% profit-growth momentum from Q1 can hold through Q2, and whether margin expansion is durable enough to justify the price-to-book re-rating the ADR has absorbed over the past month.
See the live data behind this article on ORTEX.
Open IBN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
